What You'll Want to Know About Centene's Terrific Q3 Results
Great revenue and earnings growth made investors happy with the health insurer's latest performance.
This Clean Energy Stock Continues to Prove it Can Deliver High-Powered Growth
NextEra Energy Partners' strong third-quarter results keep it on track with its impressive dividend growth plan.
Is Seattle Genetics a Good Biotech Stock to Buy Now?
It's become clear that a heavily criticized acquisition was actually a very smart move.
The deal will help grow Roku's ad business as it competes with Hulu for ad dollars.
However, one monstrous hurdle remains.
Users who have shunned expensive upgrades might shell out for a newer, cheaper device that can run the latest iOS.
Signing up late for Part B could cost you. But in some cases, you can sign up later than age 65.
The dark days of Q2 are behind the streaming giant, but how dark will Q4 be?
Clarity and communication offer compelling reasons for investment.
The chip titan will be fine in the long run, but the next few quarters are full of Chinese potholes.
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
Red flags arise regarding business practices and leadership turnover.
This newly public company helps independent advisors with key services -- and it's taking market share in an industry niche that's transitioning toward its strength.
Which stock wins in a head-to-head matchup between a leading Canadian cannabis producer and the top premium beer maker?
Marijuana growing pains aren't limited to the Canadian market.
Recurring issues with its suppliers could start causing consumers to question its food.
Here's what to watch when PayPal, Microsoft, and Twitter report their latest quarterly results.
No publicly traded company has been paying a dividend for a longer period.
It's also introducing a hard lemonade-seltzer drink next year.
Shares might look cheap, but paying off debt is a hard thing to do.
The reassessment of a failed Alzheimer's disease study looks more like an act of desperation than a clinical triumph.
Boosting your savings doesn't have to be difficult. Try these ideas and see for yourself.
A drug once thought as dead could be rising from the ashes. Does Biogen's shocking news make the stock a buy now?